Empowered Patient Podcast

Pierre Pellier is CEO of CTMA and is driven to provide better access to innovative and potentially life-saving therapies to more patients. The key is to shorten the duration of clinical trials by more quickly and efficiently identifying and recruiting potentially eligible participants.

Using the CT-Scout platform on a mobile device, doctors are prompted to ask, during a consultation, a few selected questions to determine whether a particular patient might be eligible for any of the numerous studies running at their site. Removing the need to remember major inclusion and exclusion criteria encourages doctors and investigators to broaden the search and increase recruitment.

@CScoutTm #CTMA #clinicaltrials #patientrecruitment

CTMA.fr

Listen to the podcast here

Pierre Pellier is CEO of CTMA and is driven to provide better access to innovative and potentially life-saving therapies to more patients. The key is to shorten the duration of clinical trials by more quickly and efficiently identifying and recruiting potentially eligible participants.

Using the CT-Scout platform on a mobile device, doctors are prompted to ask, during a consultation, a few selected questions to determine whether a particular patient might be eligible for any of the numerous studies running at their site. Removing the need to remember major inclusion and exclusion criteria encourages doctors and investigators to broaden the search and increase recruitment.

@CScoutTm #CTMA #clinicaltrials #patientrecruitment

CTMA.fr

Download the transcript here

Mike Rea is the Founder and CEO of IDEA Pharma and Founder of Protodigm, created to develop a new way of progressing drug development. With a fundamental understanding of what goes wrong in early-stage pharmaceutical development, Mike is eager to do more diverse opportunity-seeking for assets in early phase trials. The skunkworks model draws decision and data scientists as well as the pharma people to think outside the box.

As Mike says "But I think often in drug development, you get the silos, and people are encouraged to play nicely within the silos. The idea of taking a group of loosely structured, enthusiastic people creating an affinity group that focuses on what could you do differently for an asset, doesn't happen and it's quite hard to do within the confines of the organization."

@ProtodigmLabs #Protodigm #skunkworks #NextGenCRO #drugdevelopment

Protodigm.co

Listen to the podcast here

Mike Rea is the Founder and CEO of IDEA Pharma and Founder of Protodigm, created to develop a new way of progressing drug development. With a fundamental understanding of what goes wrong in early-stage pharmaceutical development, Mike is eager to do more diverse opportunity-seeking for assets in early phase trials. The skunkworks model draws decision and data scientists as well as the pharma people to think outside the box.

As Mike says "But I think often in drug development, you get the silos and people are encouraged to play nicely within the silos. The idea of taking a group of loosely structured, enthusiastic people creating an affinity group that focuses on what could you do differently for an asset, doesn't happen and it's quite hard to do within the confines of the organization."

@ProtodigmLabs #Protodigm #skunkworks #NextGenCRO #drugdevelopment

Protodigm.co

Download the transcript here

Renee Agular-Lucander is CEO of Calliditas Therapeutics a Sweden-based clinical-stage biopharmaceutical company focused on the rare kidney disease IgA nephropathy. While there is a genetic predisposition for this autoimmune disease, it is still not clear what triggers the condition and there is no current cure.

Renee talks about:

• Lead drug candidate Nefecon which starts at the top of the disease cascade in the ileum part of the small intestine. Delivering this disease-modifying agent directly interrupts and disrupts the beginning of the disease
• How clinical trial data is showing the value of addressing the gut-renal axis and treating this indication in an organ-specific way
• Other orphan indications that might benefit from this approach
• What the FDA priority review of Nefecon potentially means for the 1 in every 4 adults with IgAN who will eventually succumb to kidney failure.

@Calliditas1 #IgANephropathy #IgAN #Kidney #KidneyDisease #EndStageRenalDisease #AutoimmuneDisease #Nefecon #RareDisease

Calliditas.se/en

Listen to the podcast here

Renee Agular-Lucander is CEO of Calliditas Therapeutics a Sweden-based clinical-stage biopharmaceutical company focused on the rare kidney disease IgA nephropathy. While there is a genetic predisposition for this autoimmune disease, it is still not clear what triggers the condition and there is no current cure.

Renee talks about:

• Lead drug candidate Nefecon which starts at the top of the disease cascade in the ileum part of the small intestine. Delivering this disease-modifying agent directly interrupts and disrupts the beginning of the disease
• How clinical trial data is showing the value of addressing the gut-renal axis and treating this indication in an organ-specific way
• Other orphan indications that might benefit from this approach
• What the FDA priority review of Nefecon potentially means for the 1 in every 4 adults with IgAN who will eventually succumb to kidney failure.

@Calliditas1 #IgANephropathy #IgAN #Kidney #KidneyDisease #EndStageRenalDisease #AutoimmuneDisease #Nefecon #RareDisease

Calliditas.se/en

Download the transcript here

Omri Shor is Founder and CEO of Medisafe and focused on bringing resources to pharmaceutical companies so that they can better manage the entire patient journey from prescription of a specific medication throughout their daily routines and lifestyle choices. Integrating Medisafe into the engagement with patients allows key data to be collected about patterns of adherence and potential obstacles to drug adherence. Clinicians and pharmacists are also connecting through the Medisafe platform to help manage patients, particularly with comorbidities and to reduce time spent on routine tasks.

Omri emphasizes the need for patients to receive a personalized plan of action that provides real-time real-life support combining the human and digital connections. COVID-19 further illustrated the benefits of digital health technology to connect patients with the kind of support necessary to keep them on track and connected to care providers.

@medisafeApp #Medisafe App #MedicationAdherence #PatientExperience #YourHealthinYourHands #DigitalHealth #DigitalTherapeutics #COVID19

Medisafe.com

Listen to the podcast here

Omri Shor is Founder and CEO of Medisafe and focused on bringing resources to pharmaceutical companies so that they can better manage the entire patient journey from prescription of a specific medication throughout their daily routines and lifestyle choices. Integrating Medisafe into the engagement with patients allows key data to be collected about patterns of adherence and potential obstacles to drug adherence. Clinicians and pharmacists are also connecting through the Medisafe platform to help manage patients, particularly with comorbidities and to reduce time spent on routine tasks.

Omri emphasizes the need for patients to receive a personalized plan of action that provides real-time real-life support combining the human and digital connections. COVID-19 further illustrated the benefits of digital health technology to connect patients with the kind of support necessary to keep them on track and connected to care providers.

@medisafeApp #Medisafe App #MedicationAdherence #PatientExperience #YourHealthinYourHands #DigitalHealth #DigitalTherapeutics #COVID19

Medisafe.com

Download the transcript here

Tom Hallam PhD is CEO of Palisade Bio a late stage biopharmaceutical company with a focus on gastrointestinal complications from major surgery and getting patients out of the hospital more quickly. With discoveries about how digestive enzymes can hurt a patient's gastrointestinal tract, their lead asset LB1148 is a liquid that the patient drinks prior to surgery. This drug coats the entire gastrointestinal tract and inhibits digestive enzymes preventing them from attacking underlying tissue.

Palisade is also working on a breakthrough platform technology with the ability for the first time to measure the activity of digestive enzymes when they leak from the gastrointestinal tract into the blood of patients. Since these enzymes belong in the GI tract, when they appear in the blood, they can cause long-term chronic diseases and severe health consequences for patients.

@PalisadeBio #GI #gastrointestinal #ileus #adhesions #surgicalcomplications #microbiome

Palisadebio.com

Listen to the podcast here

Tom Hallam PhD is CEO of Palisade Bio a late stage biopharmaceutical company with a focus on gastrointestinal complications from major surgery and getting patients out of the hospital more quickly. With discoveries about how digestive enzymes can hurt a patient's gastrointestinal tract, their lead asset LB1148 is a liquid that the patient drinks prior to surgery. This drug coats the entire gastrointestinal tract and inhibits digestive enzymes preventing them from attacking underlying tissue.

Palisade is also working on a breakthrough platform technology with the ability for the first time to measure the activity of digestive enzymes when they leak from the gastrointestinal tract into the blood of patients. Since these enzymes belong in the GI tract, when they appear in the blood, they can cause long-term chronic diseases and severe health consequences for patients.

@PalisadeBio #GI #gastrointestinal #ileus #adhesions #surgicalcomplications #microbiome

Palisadebio.com

Download the transcript here